Board of Directors

MDxHealth was established by a management staff with extensive biotechnology industry experience.

Jan Groen, Ph.D.

Executive Member of the Board

Dr. Jan Groen joined MDxHealth in 2010 and has more than 30 years of experience in the clinical diagnostics industry, with a particular focus on emerging technologies, product development and commercialization.

Mr. Rudi Mariën

Mr. Rudi Mariën

Director, representing Biovest CVA

Mr. Mariën is currently Director of Biocartis S.A. (Switzerland). He is also President and CEO of Gengest Bvba and Biovest CommVa. 
Through his management company, Gengest BVBA, Mr. Mariën has board mandates in different stock listed (Quest For Growth, Devgen... ) and private biotech companies (Actogenix NV, Pharmaneuroboost NV, Oystershell NV…).


Mrs.Ruth Devenyns

Independent Director, representing Hasseltberg BVBA

Mrs Devenyns has a long standing experience in healthcare financing. She began her career with KBC in the Economic Research Department. She joined KBC Securities in 1995 and established KBC’s investment banking franchise in healthcare, initially as a sell-side analyst and subsequently on the banking side.

Jan Pensaert

Mr. Jan Pensaert

Director, representing Valiance Advisors LLP

Mr. Jan Pensaert is the founder and CEO/CIO of Valiance Asset Management Ltd., a specialist investment business with offices in London and Guernsey, formed in 2008.


Lieve Verplancke MD.

Independent Non-Executive Board Member

Lieve Verplancke MD was nominated as an Independent Non-Executive Director at the Company's Annual General shareholders Meeting held on 26 May 2017 in Diegem, Belgium. Ms. Verplancke, a Belgian national, began her career in 1984 with The Beecham Group (now part of GlaxoSmithKline), and has since held key management positions with Merck & Co., as well as Bristol-Myers Squibb, where she served as Managing Director, leading their Belgian/GDL subsidiary, until 2012. Ms.


Mr. Walter Narajowski

Independent Director, representing LabDx L.L.C.

Mr. Walter Narajowski currently serves as Senior Vice President and General Manager at Roka Bioscience (NASDAQ: ROKA) in San Diego. Previously, Mr. Narajowski was CEO of Pathway Diagnostics, a biomarker development and testing company, which was subsequently sold to Quest Diagnostics.


Mr. Mark Shaffar

Independent Director and Chairman of the Board

Mr. Mark Shaffar has been a consultant and advisor at Shaffar LLC since May 2014 and he also holds a mandate as an independent director of Biocartis Group NV since June 2015. He has thirty-nine years of experience in the biotechnology sector, having held numerous positions at Abbott Laboratories, including divisional vice-president of acquisition and licensing for twelve years, director of technology acquisition and licensing for seven years, and manager of licensing and acquisitions for five years. Mr.